- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Glaxo's Stiefel unit to promote Amgen's Enbrel in U.S.
London - The Stiefel unit of GlaxoSmithKline, based here, will promote Amgen’s Enbrel (etanercept) psoriasis treatment to U.S. dermatologists, Bloomberg News reports.
London
- The Stiefel unit of GlaxoSmithKline, based here, will promote Amgen’s Enbrel (etanercept) psoriasis treatment to U.S. dermatologists, Bloomberg News reports.
The partnership, according to a Glaxo statement, “has no impact” on another Amgen co-promotion agreement with Pfizer, which sells Enbrel outside the region and, with California-based Amgen, in North America. Enbrel is also approved to treat rheumatoid arthritis.
Glaxo agreed to buy Stiefel Laboratories, based in Coral Gables, Fla., for $2.9 billion in April 2009.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
